Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

The lancet. Gastroenterology & hepatology

Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.

Cardiovascular toxicology

GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.

Skin appendage disorders

Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept.

Cureus

Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.

Frontiers in endocrinology

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.

Diabetes, obesity & metabolism

Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome.

Journal of clinical medicine

GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.

Journal of clinical medicine

The ultimate peptide cheatsheet. Here's every peptide worth knowing, sorted by what it does in your body: Fat loss: → AOD-9604 → 5-Amino-1MQ → Tesofensine → MOTS-c → Setmelanotide → LIPO-C: GLP-1 receptor agonists: → Semaglutide → Tirzepatide → Retatrutide →

i've been open about my personal journey with peptides and building at the forefront of longevity. at zelta we've helped over 570+ patients lose weight with GLP-1, while semaglutide is FDA-approved with clear regulation and data behind it, the wider peptide space runs on louder https://t.co/uI7ckgtmOp

In 8 days the FDA decides the fate of the peptides half of biohacking Twitter is already taking. On July 23–24 it reviews seven of them: In 8 days the FDA decides the fate of the peptides half of biohacking Twitter is already taking. On July 23–24 it reviews seven of them: https://t.co/RGzXfWqBBx

🕵️With PCOS (polycystic ovary syndrome) being reclassified as PMOS (polyendocrine metabolic syndrome), thought I’d review the current PCOS and infertility related trials currently recruiting. (Also, a friend was asking!) Many women report meaningful improvements with PCOS

Three compounds in the typical peptide conversation are actually FDA-approved drugs semaglutide, tirzepatide, tesamorelin. The rest are not approved. The menu won't tell you which is which.

Next week, July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides being considered for inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon. Why does this matter? If these peptides are ultimately added to the https://t.co/uMJHYVSvWl

Here’s a quick breakdown of the key differences between general peptides and Khavinson-style bioregulators: Peptides are short chains of amino acids (typically 2–50). They include hormones (insulin), growth factors (BPC-157, TB-500), signaling molecules (semaglutide), and many

🧬 The “Ozempic halo” is reshaping the peptide market — and not always safely. The success of semaglutide and tirzepatide has normalized self-injection, leading some consumers to assume that all peptides are credible and safe. But FDA-approved drugs and gray-market “research https://t.co/yamtWQY0Jb